Price T Rowe Associates Inc. MD Has $8.94 Million Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Price T Rowe Associates Inc. MD lifted its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 264.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 297,101 shares of the biopharmaceutical company's stock after buying an additional 215,601 shares during the period. Price T Rowe Associates Inc. MD owned approximately 0.19% of TG Therapeutics worth $8,944,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in TGTX. Vanguard Group Inc. raised its holdings in shares of TG Therapeutics by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company's stock worth $469,454,000 after acquiring an additional 209,190 shares during the last quarter. Clearbridge Investments LLC acquired a new stake in shares of TG Therapeutics in the fourth quarter valued at about $55,237,000. Charles Schwab Investment Management Inc. lifted its holdings in TG Therapeutics by 7.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company's stock worth $38,212,000 after buying an additional 84,904 shares in the last quarter. Invesco Ltd. increased its holdings in TG Therapeutics by 1.2% during the 4th quarter. Invesco Ltd. now owns 929,743 shares of the biopharmaceutical company's stock worth $27,985,000 after purchasing an additional 10,989 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of TG Therapeutics by 10.5% in the 4th quarter. Bank of New York Mellon Corp now owns 923,488 shares of the biopharmaceutical company's stock worth $27,797,000 after purchasing an additional 87,679 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $40.80.

TG Therapeutics Price Performance

TG Therapeutics stock traded down $0.01 on Wednesday, reaching $34.85. The company's stock had a trading volume of 3,583,516 shares, compared to its average volume of 3,029,138. TG Therapeutics, Inc. has a twelve month low of $15.16 and a twelve month high of $46.48. The business's fifty day moving average price is $38.86 and its 200 day moving average price is $33.42. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The company has a market cap of $5.53 billion, a price-to-earnings ratio of -348.47 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The business had revenue of $120.86 million during the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. TG Therapeutics's revenue was up 90.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.07) earnings per share. Equities analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.